SCP
GTBP icon

Silverleafe Capital Partners’s GT Biopharma GTBP Stock Holding History

Silverleafe Capital Partners’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,500
Closed -$708K – 91
2021
Q3 		$708K Buy
3,500
+33
+1% +$9.93K 0.28% 52
2021
Q2 		$1.61M Buy
+3,467
New +$1.44M 0.62% 48

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Silverleafe Capital Partners's GTBP Position: Q4 2021 in Review

Silverleafe Capital Partners sold out of GT Biopharma (GTBP) in Q4 2021, closing a stake of 3,500 shares — an estimated $708K sold.

Silverleafe Capital Partners first reported a position in GTBP in Q2 2021 and held it in 2 quarters. The position peaked at $1.61M in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q4 2021.

  • Silverleafe Capital Partners reported no remaining GT Biopharma position as of Q4 2021 after selling out during the quarter.
  • Silverleafe Capital Partners sold 3,500 GT Biopharma shares in Q4 2021, an estimated $708K.
  • Silverleafe Capital Partners first reported a position in GT Biopharma in Q2 2021 and held it in 2 quarters.
  • Silverleafe Capital Partners's GT Biopharma position peaked at $1.61M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2021.

Based on Silverleafe Capital Partners's 13F filing for Q4 2021, filed 4 Jan 2022.